Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03552029
Title Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.

acute myeloid leukemia


Milademetan Tosylate + Quizartinib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Ronald Reagan Medical Center, UCLA Los Angeles California 90095 United States Details
Yale Cancer Center New Haven Connecticut 06510 United States Details
University of Kansas Cancer Center Fairway Kansas 66205 United States Details
Rogel Cancer Center, University of Michigan Ann Arbor Michigan 48109 United States Details
Roswell Park Comprehensive Cancer Center Buffalo New York 14263 United States Details
Duke University Cancer Center Durham North Carolina 27710 United States Details
Sidney Kimmel Cancer Center, Thomas Jefferson University Philadelphia Pennsylvania 19107 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field